Foundayo Price Comparison: Is the New UK Weight Loss Pill Affordable?

Foundayo is a new once-daily tablet from Eli Lilly that was approved in the UK on 10 August 2026 for weight loss and poorly controlled type 2 diabetes. 

This medication is set to launch in the UK later in August through private prescription, according to an Eli Lilly spokesperson who spoke to Reuters. The tablet will also have a lower UK private list price than Mounjaro.

At the time of Foundayo's UK approval, Mounjaro's private list price was around £330 for a month's supply. You are looking at a Foundayo treatment plan that could be priced below £330 per month, although the final cost may still be subject to other factors.

While the UK price has not been confirmed, this Foundayo price comparison guide explains what we know so far and how its expected cost fits into the private weight loss market.

Foundayo UK Price Comparison Across Providers

UK private providers have started publishing prices for Foundayo ahead of its wider availability. These prices provide an early indication of what patients may pay for the new weight-loss tablet, although the final cost can vary between providers and doses. 

The current prices are useful for comparing the market, but you should not treat them as the final cost, as both availability and pricing may change. 

Foundayo UK Price: What Do We Know?

Eli Lily’s projection that the tablets will be priced below Mounjaro’s UK list price gives some indication of its position in the market, but the final cost could still depend on how private providers charge for the treatment.

Until Lily launches this medication, patients should check with UK registered pharmicies such as Curely for price updates. You shouldn't rely on old US-to-UK currency conversions.

Still, what you pay for the Foundayo dosages may differ based on:

• private pharmacies and their prescribing services
• wholesale arrangements
• taxes
• clinical fees and the wider UK medicines market

The UK National Health Service is funded by taxes and helps eligible patients access prescription drugs and other medications.

Foundayo is currently not one of the treatment options since it's not available either privately or through the NHS. 

Any future NHS access will depend on whether the National Institute for Health and Care Excellence (NICE) recommends this orforglipron pill for funding.

Foundayo Price by Dose

Daily Oral GLP-1 Treatment

Foundayo

Helps reduce appetite and hunger.

Shop Now

Just like most weight loss drugs, Foundayo is designed to start at a low dose and increase gradually. 

The UK-approved strengths are:

• 0.8 mg
• 2.5 mg
• 5.5 mg
• 9 mg
• 14.5 mg
• 17.2 mg 

The dose can increase at intervals of at least 30 days, depending on the response and how well the patient tolerates the treatment (Eli Lilly and Company, 2026). 

Because of this, your first month's orforglipron price may not be the same as your ongoing cost. 

What is Included in the Foundayo Price?

The exact package will depend on the pharmacy or weight loss service you use.

You may pay for:

• The prescription medicine
• The clinical assessment
• Prescription processing
• Follow-up consultations
• Dose reviews
• Delivery
• Ongoing clinical support

Some providers offer an all-inclusive monthly price, while others charge separately for consultation or delivery. Curely, a registered UK pharmacy, gives you expert advice, discreet shipping, incentives on shipping, and safe and secure delivery all in one package.

Because prices and services vary, compare the total amount you will pay, not just the advertised medicine price.

This can help you find the option that offers the maximum monthly savings while still providing the clinical support you need.

Foundayo vs Other Weight Loss Options

At present, the most accurate way to view the UK market is:

Foundayo sits in a growing group of prescription weight loss medications.

The main UK comparisons include:

• Foundayo (orforglipron): daily oral GLP-1 tablet
• Mounjaro (tirzepatide): once-weekly injection
• Wegovy (semaglutide): once-weekly injection
• Wegovy tablet (semaglutide): oral treatment taken according to specific dosing instructions
• Saxenda (liraglutide): daily injection
• Orlistat: an older oral weight loss medicine that works differently from GLP-1 medicines. 

The Orlistat 120 mg dose is a prescription-only drug, while the lower 60 mg dose is available among over-the-counter medicines in UK pharmacies

Even though these medicines may help with weight management, you should not treat them as interchangeable products.

Foundayo is a GLP-1 receptor agonist, whereas Mounjaro is different because tirzepatide activates both GIP and GLP-1 receptors. Wegovy, on the other hand, contains semaglutide, another GLP-1 receptor agonist.

The right option for you depends on your medical history, expected benefits, side effects, dosing preferences and affordability.

Foundayo Price vs Mounjaro

Mounjaro is currently one of the main weight management medicines available in the UK.

It contains tirzepatide and is given once a week using an injection pen. 

Eligible patients in England may receive Mounjaro through the NHS. This changes the Foundayo price comparison because these patients do not have to pay the full private price for the drug.

The current Mounjaro UK price reflects typical private prices that range from roughly £130 to more than £300 per month, with higher strengths costing more. This is also the figure Eli Lily, through their spokesperson, projected the Foundayo tablet price to beat when they launch it.

As for weight loss results, Foundayo's phase 3 data showed average weight loss of around 11% at the highest approved dose in one major study, although results vary between individuals and trials. (Wharton et al., 2025). 

Tirzepatide has produced larger average reductions in some clinical studies. However, comparing percentages from different trials directly can be misleading because studies involve different participants, doses, durations, and study designs.

Foundayo Price vs Injectable Wegovy

Convenient once-weekly dosing

Wegovy injection

Supports appetite control and weight loss

Shop Now

Wegovy contains semaglutide and is taken once a week as an injection for weight management.

In England, NHS access to semaglutide for obesity is through specialist weight management services and depends on eligibility. Private treatment is also available through registered providers, such as Curely.

The current UK price comparisons put private monthly costs at around £90 to £240 or more for commonly used strengths. Higher-dose options may cost more. 

The main cost advantage of Foundayo may therefore depend on the eventual UK launch price and the dose required.

There is also a practical difference as Wegovy injection is weekly, while Foundayo is taken once a day.

Foundayo Price vs the Wegovy Pill

The Wegovy pill is also a new UK oral GLP-1 option for weight management. Unlike Foundayo, these tablets are available for private prescriptions. 

UK product information lists Wegovy tablet strengths as 1.5 mg, 4 mg, 9 mg and 25 mg. Patients use this pill for weight management alongside a reduced-calorie diet and increased physical activity. 

Wegovy pill price is currently around £199 to £399 per month privately, depending on the dose and pharmacy. 

Foundayo and the Wegovy pill are both once-daily oral GLP-1 treatments, but their dosing requirements differ. The Wegovy pill has specific administration instructions that require it to be taken on an empty stomach with a limited amount of water and followed by a waiting period before eating or taking other oral medicines. Foundayo doesn't have such restrictions. 

This could make Foundayo more convenient for people who have unpredictable morning routines. However, convenience does not automatically mean better weight loss.

In the ATTAIN-1 trial, people taking the highest dose of Foundayo who remained on treatment lost an average of 12.4% of their body weight after 72 weeks. The OASIS 4 trial found that people taking 25mg oral semaglutide lost an average of 16.6% of their body weight after 64 weeks when treatment adherence was accounted for, compared with 2.7% with placebo. (Bergmann et al., 2025). 

Clinical results showed weight loss of 13.6% versus 2.2% with placebo during this trial. 

These figures suggest that both tablets can deliver substantial weight loss, but they do not establish that one is more effective than the other. The trials were conducted separately, with differences in study design and participants, so the results should not be treated as a head-to-head comparison.

Price vs Weight Loss Results

Cost is only useful when considered alongside expected treatment benefits.

Foundayo clinical data show meaningful average weight loss. The ATTAIN-1 trial found that Foundayo may help patients lose around 12.4 kgs with varying results by dosage. (Wharton et al., 2025). 

Mounjaro and Wegovy have also achieved substantial weight loss in their respective SURMOUNT and STEP clinical trials. However, you should not assume that the highest percentage reported in one medicine's study will be the result you personally achieve. (Jastreboff et al., 2022).

Individual response varies due to:

• Starting weight
• Dose reached
• Treatment duration
• Appetite response
• Other medical conditions
• Other medicines
• Diet and physical activity
• How well treatment is tolerated

This means the cheapest medicine may not be the most cost-effective choice if it does not provide an adequate response or cannot be tolerated.

Price vs Convenience

Foundayo is taken once daily and does not require the food and water restrictions associated with oral semaglutide. It is also not an injection. 

For some patients, that simplicity may make it easier to stay consistent.

Daily treatment still requires remembering a tablet every day, so a weekly injection may be easier for someone who dislikes daily medication.

There is no universally most convenient option.

The most suitable option may depend on whether the difference in price is worthwhile for the dosing routine and administration requirements that come with each treatment. 

Cost over Time

Weight management treatment may continue for many months, and the cost can change as the dose changes.

The UK’s weight loss medications pricing illustrates how this works. Most starting doses are cheaper than several of the higher strengths. If the patient progresses through the full dosing schedule, their average monthly cost over a year will be higher than multiplying the starting price by 12. 

The same principle applies to Mounjaro and Wegovy. Higher strengths can cost more through private providers. 

So, when comparing treatments, ask:

• What is the starting monthly cost?
• What could the cost be at the maintenance dose?
• Is delivery included?
• Are consultations included?
• Are follow-up appointments included?
• Does the provider charge a membership fee?
• Are there introductory offers that expire?
• What happens if treatment is stopped or changed?

These questions give you a much clearer picture of the total cost.

The Cost of Switching Treatments

Switching treatments can involve costs beyond the price of the new medicine. You may need to pay for another consultation or a new prescription, depending on the provider and treatment you are moving to. 

For example, if you are switching from Wegovy or Mounjaro to Foundayo, you may have to pay a consultation fee before the new treatment. Medication costs for subsequent monthly purchases may also differ from the price of your previous Foundayo prescription fill.

Private vs NHS Cost

The cost of Foundayo is not the same for private prescriptions and those obtained through the NHS. Private patients pay for the medication and any associated clinical services in full. NHS treatment, on the other hand, provides drugs to eligible patients at cheaper prices.

For a private prescription, the total cost may include the medicine itself, an assessment, prescription fees, dispensing fees, or delivery charges. Still, these costs vary between providers. 

• Mounjaro is being introduced through a phased NHS rollout for eligible patients. NHS England says the rollout prioritises people with obesity and significant weight-related health risks. (NHS England, 2026) 
• Wegovy is also available through NHS specialist weight management services for eligible patients.
• Foundayo has only just received UK regulatory approval and is expected to launch privately. NHS funding is a separate question and would depend on future UK health technology assessment and commissioning decisions.

Who Is Foundayo For?

UK weight-management criteria use BMI alongside weight-related health conditions, similar to the criteria already used for medicines such as Mounjaro. 

Therefore, Foundayo may be for:

• Adults with a BMI of 30 kg/m² or above: This falls within the obesity category used for prescription weight-management treatment.
• Adults with a BMI of 27 kg/m² to below 30 kg/m²: Treatment may be considered when the person also has at least one weight-related health condition, such as high blood pressure, abnormal cholesterol levels, sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes. 
• Adults looking for an oral treatment: Foundayo is an oral option alongside existing injectable weight-loss treatments.
• People who meet the clinical requirements

A prescriber should consider BMI, medical history, existing health conditions and current medicines before deciding whether treatment is appropriate.

Who Is Foundayo Not For?

Foundayo will not be suitable if you:

• Do not meet the required BMI and health criteria
• Have certain thyroid cancer risks: Orforglipron's prescribing information includes restrictions relating to a history of medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2. 
• Are pregnant: Weight-loss treatment is not intended for use during pregnancy. Anyone who is pregnant, planning a pregnancy or breastfeeding should discuss this with a healthcare professional before considering treatment.
• Are taking other medicines that could interact with Foundayo: Your prescriber should review your current medicines, including oral medicines, before treatment.
• Are on oral contraceptives: Because GLP-1 medicines can affect gastric emptying, people taking birth control pills may need specific contraceptive advice.

Foundayo Side Effects

Like other GLP-1 medicines, Foundayo can cause side effects, particularly digestive symptoms:

• Nausea
• Constipation
• Diarrhoea
• Vomiting
• Indigestion
• Abdominal discomfort
• Bloating
• Burping
• Acid reflux

Side effects can become more noticeable as the dose increases. Across the two weight-management trials, around 8% of people taking Foundayo permanently discontinued treatment because of adverse reactions, compared with 3% of people taking placebo. Most discontinuations were linked to gastrointestinal side effects. (Eli Lilly and Company, 2026).

Serious side effects may include pancreatitis, gallbladder problems, severe gastrointestinal reactions, dehydration, trouble swallowing,  and kidney problems. Anyone experiencing severe or persistent symptoms should seek medical advice.

Also, the risk of hypoglycaemia increases when Foundayo is used with insulin or sulfonylureas. A healthcare professional may need to reduce the dose of insulin or the sulfonylurea to lower this risk. 

How Curely Can Help UK Patients Compare Options

Curely offers a platform for UK patients to compare weight-loss treatments at the point where a choice needs to be made. Our online consultation assesses whether you qualify for treatment, taking into account factors such as your personal or family history, and then allows you to consider the medicines that may be suitable for you. 

The service also gives patients a way to reassess their treatment if an existing medicine is not working as expected. We support switching between weight-loss medicines, with our prescribing team able to review your current treatment and determine whether another option may be appropriate. 

Curely's weight-loss range includes Mounjaro, Wegovy injection and the Wegovy pill. The treatments cover both weekly injections and daily tablets for new and existing patients.

Explore Your Weight-Loss Treatment Options with Curely 

Foundayo may be an interesting addition to the UK weight-loss market, but you do not have to wait for its private launch to explore treatment. Curely makes it possible to look at established prescription options and decide what may suit your needs now.

Therefore, if you are considering the Wegovy pill, Mounjaro or another available treatment, you can start with Curely's online consultation today and see whether you are eligible. The process takes place from home, with treatment decisions made following a clinical review.

Take the next step and explore your options with Curely today.

Start your Curely assessment.

FAQs

What is the Best Price for Foundayo?

There is currently no confirmed UK private orforglipron pill price, so it is not possible to identify the best value for your money.

Foundayo was authorised for use in the UK on 10 August 2026, but it is not currently available through the NHS. Eli Lilly has indicated that the UK private launch will have a lower list price than Mounjaro, although the exact figure has not been announced.

How Much Does Foundayo Cost without an Insurance Coverage?

There are currently no confirmed UK out-of-pocket costs for Foundayo. The UK lacks a commercial drug insurance plan like in the US where private health insurance and specific US federal healthcare programs can determine how much you pay for medicines. 

In the UK, eligible patients can receive NHS-funded treatment once a medicine has been approved for NHS use. Patients who choose private treatment pay the private provider directly.

At a time when private weight-loss treatment can be expensive, Curely lists Foundayo at a starting price of £59.99 for the 0.8 mg dose. This is one of the best offers for orforglipron you will find anywhere in the UK. 

So, if you want to start weight loss treatment at a more manageable budget, Curely pricing lets you do just that. 

Is Foundayo the Same as Tirzepatide?

No. Foundayo contains orforglipron, an oral GLP-1 receptor agonist. It is designed to be taken once daily as a tablet. Tirzepatide is a dual GIP and GLP-1 receptor agonist and is the active ingredient in Mounjaro. This weight loss medication is administered as a once-weekly injection.

The medicines, therefore, belong to related but distinct treatment categories. Both act on hormone pathways involved in appetite, food intake and blood glucose regulation, but they do not work in exactly the same way.

Which is Better for Weight Loss, Foundayo or Mounjaro?

Neither can be considered universally better for weight loss. Mounjaro (tirzepatide) has produced greater average weight loss than Foundayo (orforglipron) in their respective clinical trials, but the medicines have not been compared directly in the same trial.

The medications also differ in how they are taken. Foundayo is a once-daily oral tablet, unlike Mounjaro, which is administered as a once-weekly injection. 

The most appropriate choice depends on your health, weight-loss goals, response to treatment, potential side effects, cost, self-savings options, and preference for a tablet or injection.

Final Verdict

Foundayo has already attracted attention because it offers a different approach to weight-loss treatment. Unlike Mounjaro and injectable Wegovy, Foundayo is a once-daily oral GLP-1 medicine containing orforglipron. That means it can be taken as a tablet rather than requiring a weekly injection, which may appeal to people who prefer an oral treatment.

Its formulation also distinguishes it from the Wegovy tablet. Foundayo can be taken without the same food and water restrictions associated with oral semaglutide. This may make the daily routine simpler for some patients, although convenience is only one factor when comparing treatments.

Clinical trials have shown that Foundayo can produce meaningful weight loss, with greater average reductions seen at higher doses. Other medicines, including tirzepatide and semaglutide, have also produced substantial weight loss in their respective clinical trials

References

• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. 
• NHS England. (2026). Interim commissioning guidance: NICE TA1026 tirzepatide. NHS England. 
• Medicines and Healthcare products Regulatory Agency. (2026, August 10). UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. GOV.UK. 
• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002 
• Ananthan, P. (2026, August 10). Eli Lilly's weight-loss pill secures first European nod in Britain. Reuters.